Potential drug–drug interactions in patients with cardiovascular diseases: findings from a prospective observational study

References

• Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA. 2017;317(2):165–182.
   PubMed Web of Science ®Google Scholar
• Isetts BJ, Schondelmeyer SW, Artz MB, Lenarz LA, Heaton AH, Wadd WB, et al. Clinical and economic outcomes of medication therapy management services: the Minnesota experience. J Am Pharm Assoc. 2008;48(2):203–214.
   Google Scholar
• Murtaza G, Khan MYG, Azhar S, Khan SA, Khan TM. Assessment of potential drug–drug interactions and its associated factors in the hospitalized cardiac patients. Saudi Pharm J. 2016;24(2):220–225.
   PubMed Web of Science ®Google Scholar
• Kovačević M, Vezmar Kovačević S, Radovanović S, Stevanović P, Miljković B. Adverse drug reactions caused by drug–drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items. Curr Med Res and Opin. 2019;35(11):1873–1883.
   PubMed Web of Science ®Google Scholar
• Kovačević M, Vezmar Kovačević S, Miljković B, Radovanović S, Stevanović P. The prevalence and preventability of potentially relevant drug–drug interactions in patients admitted for cardiovascular diseases: a cross-sectional study. Int J Clin Pract. 2017;71(10):e13005. https://doi.org/10.1111/ijcp.13005.
   Web of Science ®Google Scholar
• Shakeel F, Khan JA, Aamir M, Hannan PA, Zehra S, Ullah I. Risk of potential drug–drug interactions in the cardiac intensive care units: a comparative analysis between 2 tertiary care hospitals. Saudi Med J. 2018;39(12):1207–1212.
   Web of Science ®Google Scholar
• Diksis N, Melaku T, Assefa D, Tesfaye A. Potential drug–drug interactions and associated factors among hospitalized cardiac patients at Jimma University Medical Center, Southwest Ethiopia. SAGE Open Med. 2019;7:2050312119857353.
   Web of Science ®Google Scholar
• Sharma S, Chhetri HP, Alam K. A study of potential drug–drug interactions among hospitalized cardiac patients in a teaching hospital in Western Nepal. Indian J Pharmacol. 2014;46(2):152–156.
   Web of Science ®Google Scholar
• Abdela OA, Bhagavathula AS, Getachew H, Kelifa Y. Risk factors for developing drug-related problems in patients with cardiovascular diseases attending Gondar University Hospital. Ethiopia J Pharm Bioallied Sci. 2016;8(4):289–295.
   PubMedGoogle Scholar
• Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc. 2001;41(2):192–199.
   Google Scholar
• Krähenbühl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krähenbühl S. Drug-related problems in hospitals. Drug Saf. 2007;30(5):379–407.
   PubMed Web of Science ®Google Scholar
• Janchawee B, Wongpoowarak W, Owatranporn T, Chongsuvivatwong V. Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand. J Clin Pharm Ther. 2005;30(1):13–20.
   PubMed Web of Science ®Google Scholar
• Zheng WY, Richardson L, Li L, Day R, Westbrook J, Baysari M. Drug–drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. Eur J ClinPharmacol. 2018;74(1):15–27.
   Web of Science ®Google Scholar
• Ismail M, Iqbal Z, Khattak MB, Khan MI, Javaid A, Khan TM. Potential drug–drug interactions in cardiology ward of a teaching hospital. Health Med. 2012;6:1618–1624
   Google Scholar
• Patel VK, Acharya LD, Rajakannan T, Surulivelrajan M, Guddattu V, Padmakumar R. Potential drug interactions in patients admitted to cardiology wards of a south Indian teaching hospital. Austaras Med J. 2011;4(1):9–14.
   Google Scholar
• Namazi S, Moosavi N. The evaluation and management of drug–drug interactions in patients on cardiovascular and cardiosurgery wards in Namazi and Shahid Faghihi hospitals, Iran, Shiraz. Res Pharm Sci. 2012;7(5):911
   Google Scholar
• Zubair F, Nawaz SK, Nawaz A, Nangyal H, Amjad N, Khan MS. Prevalence of cardiovascular diseases in Punjab, Pakistan: a cross-sectional study. J Public Health. 2018;26(5):523–529.
   Google Scholar
• Javaid F, Hanif S, Syed MA, Jawad S, Afzal S, Malik R, et al. Incidence of potential drug–drug interactions in patients with cardiovascular complications due to the trend of polypharmacy prescription in Pakistan. Lat Am J Pharm. 2017;36(6):1210–1217
   Web of Science ®Google Scholar
• Abdullah A, Ahmad N, Atif M, Khan S, Wahid A, Ahmad I, et al. Treatment outcomes of childhood tuberculosis in three districts of Balochistan, Pakistan: findings from a retrospective cohort study. J Trop Pediatr. 2020. https://doi.org/10.1093/tropej/fmaa042
   Web of Science ®Google Scholar
• The Express Tribune. Civil Hospital, Quetta: Lack of facilities paint dismal picture of health sector. The Express Tribune.https://tribune.com.pk/story/1620711/civil-hospital-quetta-lack-facilities-paint-dismal-picture-health-sector (22 January, 2021, date last accessed)
   Google Scholar
• Daniel, W. W. (1995). Biostatistics: a foundation for analysis in the health sciences. New York-Chichester-Brisbane-Toronto-Singapore
   Google Scholar
• Lexicomp Online®, LexiInteract. Hudson, Ohio: Lexi` mp, Inc. (Accessed on 20 December, 2020).
   Google Scholar
• Kheshti R, Aalipour M, Namazi S. A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract. 2016;5(4):257–263.
   PubMed Web of Science ®Google Scholar
• Nusair MB, Al-Azzam SI, Arabyat RM, Amawi HA, Alzoubi KH, Rabah AA. The prevalence and severity of potential drug–drug interactions among adult polypharmacy patients at outpatient clinics in Jordan. Saudi Pharm J. 2020;28(2):155–160.
   PubMed Web of Science ®Google Scholar
• Štuhec M, Potočin I, Stepan D, Ušaj L, Šter MP, Beović B. Potential drug interactions with antibacterials in long-term care facilities analyzed by two interaction checkers. InterJ Clin Pharm. 2019;41(4):932–938.
   Web of Science ®Google Scholar
• Mosca L, Barrett-Connor E, Kass WN. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation. 2011;124(19):2145–2154.
   PubMed Web of Science ®Google Scholar
• Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet Genomics. 2010;20(7):463–465.
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metabol Dispos. 2010;38(1):92–99.
   PubMed Web of Science ®Google Scholar
• Bundhun PK, Teeluck AR, Bhurtu A, Huang W-Q. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty? A systematic review and meta-analysis of recently published studies (2012–2016). BMC Cardiovasc Disord. 2017;17(1):3https://doi.org/10.1186/s12872-016-0453-6
   Google Scholar
• Members WC, Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;122(24):2619–2633.
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metabol Dispos. 2011;39(11):2020–2033.
   PubMed Web of Science ®Google Scholar
• Zvyaga T, Chang S-Y, Chen C, Yang Z, Vuppugalla R, Hurley J, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metabol Dispos. 2012;40(9):1698–1711.
   PubMedGoogle Scholar
• Arbel Y, Birati EY, Finkelstein A, Halkin A, Kletzel H, Abramowitz Y, et al. Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: a prospective, randomized, crossover study. Clin Cardiol. 2013;36(6):342–346.
   PubMed Web of Science ®Google Scholar
• Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-proton pump inhibitor drug–drug interaction and risk of adverse clinical outcomes among PCI-treated ACS patients: a meta-analysis. J Manag Care Spec Pharm. 2016;22(8):939–947.
   PubMed Web of Science ®Google Scholar
• Hulot J-S, Collet J-P, Silvain J, Pena A, Bellemain-Appaix A, Barthélémy O, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19* 2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010;56(2):134–143.
   PubMed Web of Science ®Google Scholar
• Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012;125(8):978–986.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Eng J Med. 2010;363(20):1909–1917.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989–997.
   PubMed Web of Science ®Google Scholar
• Tim Meadows, Medicines Information Pharmacist, Midlands and East Medicines Advice Service. Do proton pump inhibitors reduce the clinical efficacy of clopidogrel? 2019. https://www.sps.nhs.uk/wp-content/uploads/2019/07/UKMI_QA_Clopidogrel-PPI_July_2019.pdf (22 January 2021, date last accessed)
   Google Scholar
• Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM. 2005;98(7):493–497.
   PubMed Web of Science ®Google Scholar
• Jabbal S, Anderson W, Short P, Morrison A, Manoharan A, Lipworth BJ. Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD. QJM. 2017;110(12):785–792.
   Web of Science ®Google Scholar
• Egger SS, Bravo AER, Hess L, Schlienger RG, Krähenbühl S. Age-related differences in the prevalence of potential drug–drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging. 2007;24(5):429–440.
   PubMed Web of Science ®Google Scholar
• Lopez-Martin C, Siles MG, Alcaide-Garcia J, Felipe VF. Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience. Int J Clin Pharm. 2014;36(6):1251–1259.
   PubMed Web of Science ®Google Scholar
• Graabæk T, Kjeldsen LJ. Medication reviews by clinical pharmacists at hospitals lead to improved patient outcomes: a systematic review. Basic Clin Pharmacol Toxicol. 2013;112(6):359–373.
   Web of Science ®Google Scholar
• Georgiev KD, Hvarchanova N, Georgieva M, Kanazirev B. The role of the clinical pharmacist in the prevention of potential drug interactions in geriatric heart failure patients. Int J Clin Pharm. 2019;41(6):1555–1561.
   Web of Science ®Google Scholar
• Tannenbaum C, Sheehan NL. Understanding and preventing drug–drug and drug–gene interactions. Expert Rev Clin Pharmacol. 2014;7(4):533–544.
   PubMed Web of Science ®Google Scholar
• AlRuthia Y, Alkofide H, Alosaimi FD, Sales I, Alnasser A, Aldahash A, et al. Drug–drug interactions and pharmacists’ interventions among psychiatric patients in outpatient clinics of a teaching hospital in Saudi Arabia. Saudi Pharm J. 2019;27(6):798–802.
   Web of Science ®Google Scholar
• Moura CS, Prado NM, Belo NO, Acurcio FA. Evaluation of drug–drug interaction screening software combined with pharmacist intervention. Int J Clin Pharm. 2012;34(4):547–552.
   Web of Science ®Google Scholar